adjust dilut earn per share ep defin report
relat cost discontinu oper certain signific
took anoth look model near end ep intact
increas trim thereaft price-to-earnings multipl
estim repres discount global pharma univers averag
continu believ growth prospect reflect valuat
ep estim intact consist consensu
middl guidanc rang ep increas
vs consensu eliqui deliv better-than-expect perform
factor exclus lyrica mid vs previous ep
project reduct last-publish number
impli ep compound-annual-growth-rate unchang last model
part due lower forecast sale lower fy revenu estim
vs consensu sale increas
larg higher lyrica forecast see revenu
project thereaft lower reduct roughli
equal split innov essenti busi
revenu forecast
may announc posit top-lin result phase studi lyrica oral solut
adjunct therapi partial onset seizur pediatr epilepsi patient one month less
four year age studi part post-market requir lyrica
data pediatr epilepsi clinic studi submit fda support
applic pediatr exclus given posit studi assum
exclus grant extend june versu decemb
current increas lyrica sale estim
lyrica forecast year chang significantli
lower degre forecast margin expans time part
gener encourag assumpt nonetheless show oper margin
roughli unchang sinc last-publish model flat vs
previous vs previous compound basi
factor gross margin growth consist expans sale
 increas declin sg
pleas see page report import disclosur
outperform rate stock key averag bottom-lin growth
improv innovation/new product flow solid dividend yield
compel valuat share appear under-valued sotp basi
xeljanz eu approv uc
posit chmp decis june/april
xtandi approv non-metastat cprc
juli pdufa eu
tafamidi full ph data ttr
cardiomyopathi posit top-
decis consum busi futur
everi earli stage product
launch achiev
ibranc palbociclib adopt even
brisk expect
pipelin achiev greater expect
accret potenti break-up
compani lead greater valuat
pfizer inc global biopharmaceut compani divers portfolio pharma product
cover area cardiovascular anti-infect anti-inflammatori oncolog
metabol diseas other also strong vaccin portfolio consum product
segment array brand product
compani data cowen compani
compani data cowen compani
innov eu lc ex develop emerg develop emerg eu lc ex develop emerg total ex us eu lc ex develop emerg cowen
compani data cowen compani
compani data cowen compani
compani data cowen compani
compani data cowen compani
compani data cowen compani
compani data cowen compani
compani data cowen compani
compani data cowen compani
compani data cowen compani
compani data cowen compani
compani data cowen compani
compani data cowen compani
innov box warn remov patent expir could get pedi exclusivitychampix/chantix eu lc ex fx champix/chantix warn relax patent expir septemb develop emerg smoke cessat pressur suicid concerns/label revenu record line begin innov exp appli pedi exclus lyrica cr offer conveni advantagelyrica develop emerg monotx central neuropath pain due spinal injuri post op pain cr qd bid w/lli phase chronic low back cancer pain oa sign sx data filingtot innov eu lc ex fx enbrel launch lifmior enbrel dual brand yet launchedenbrel develop emerg total ex us arthriti right foreign mkt ex /canada patent expir eu xeljanz ra ucxeljanz eu lc ex fx xeljanz ra file po chmp apr modifi releas po chmp jun develop emerg oral topic inhibitor mild/moder atop dermat pedi/adult approv via anacor acq close estim peak sale inhibitor atop dermat phase breakthrough rheumatoid arthriti phase ii ibd phase rheumatoid arthriti phase rheumatoid arthriti alopecia areata ulcer coliti crohn diseas phase psoriasi alopecia areata ulcer coliti crohn diseas phase blocker ulcer coliti biolog phase iitot innov cowen
compani data cowen compani
innov sulfat er/naltrexon co-formul launch recal supplement approv approv re-launch mu-typ opiod receptor agonist sever pain approv pain innov eu lc ex fx genotropin develop emerg hormon children diabet inhibitor mrk/pfe split approv eu indic long bone fractur spinal growth hormon antagonist acromegali via coa-carboxylas inhibitor non-alcohol steatohepat nash fast khk inhibitor nash premarin osteoporosis/menopaus symptom market eu market author innov drugsbenefix eu lc ex fx benefix develop emerg competit pressur cowen
compani data cowen compani
innov drug cont drefacto/xyntha eu lc ex fx refacto/xyntha develop emerg xyntha albumin free competit pressuresviagra essenti health exp gener launchedrapamun eu lc ex fx rapamun exp eurapamun develop emerg kidney transplant reject oral tab supportsvyndaqel tafamidi dissoci inhib polyneuropathi approv eu file cardiomyopathi achiev endpt myostatin inhib duchenn muscular dystrophi fast track/orphan us/eu phase therapy/coagul factor ix hemophilia biolog breakthru/orphan phase gtx hemophilia biolog fast track/orphan us/eu phase overact bladder eu somatrogon agonist gh defici biolog orphan statu us/eu piii adult piii pedi rivipansel antagonist vaso-occlus crisi associ sickl cell diseas fast track orphan eu phase iiixiaflexnmnmpf ex-u right agreement end alfa gaucher diseas approv protalixoth gip innov innov innov cowen
compani data cowen compani
innov tyrosin kinas inhibitor approv adjuv rcc patent expir februari eu lc ex fx sutent expir juli file adjuv rccsutent develop emerg gleevec-resist gist rcc gu gi ibranc line advanc breast cancer approv label bc set inibr eu lc ex fx trial base paloma develop emerg inhibitorxalkori tx advanc nsclc small percent patient lung cancer patient xalkori eu lc ex fx xalkori develop emerg oral c-met inhibitor competit clipsinlyta lung thyroid hepat melanoma glioblastoma liver combo keytruda combo xalkori rccinlyta eu lc ex fx inlyta develop emerg vegf tyrosin kinas inhibitor file us eu brca-mut breast cancer revenu gross profit split astella record line start calicheamycin conjug r/r approv eu abl/src kinas inhibitor approv line inhib nsclc file phase penetr blood brain smoothen antagonist aml phase orphan statu inhib merck kgaa market merkel cell line bladder nsclc ovarian renal gastric urotheli scchn cml io asset pan-her inhibitor egfr nsclc file previous tx advanc studi market renal cell cancer mantl cell fgn mkt pursu pat exp ex total innov cowen
compani data cowen compani
innov recommend adult post capita dataprevnar eu lc ex fx prevnar reimburs gain country-by-countri basisprevnar develop await reimbursementprevnar emerg valent pneumococc conjug vaccineprevnar eu lc ex fx prevnar estab emerg enceph market countri acquir diseas approv eu adolesc young difficil coliti vaccin prophylact fast track phase staphylococcu aureu vaccin prophylact phase ii fast non-invas pneumococc infect phase market acquir group vaccin spain biotech acquir innov vaccin innov productsadvil consum innov innov innov pfizer total sale cowen
compani data cowen compani
essenti gener launch eu lc ex fx lipitor basic patent expir pedi extensionlipitor develop basic patent expir emerg patent expir juli chinalipitor cholesterol reduct market growth anticipatednorvasc eu lc ex fx norvasc develop emerg competit erod franchis temper emerg rowcardura eu lc ex fx cardura develop emerg competit erod franchis temper emerg rowcaduet eu lc ex fx caduet develop emerg combin gener launchedfragmin lmw heparin ucad hip abdom surg pat exp fragmin eu lc ex fx fragmin develop emerg hypertens post atrial arrhythmia gener launch competit pressur litig essenti cowen
compani data cowen compani
essenti expir eu lc ex fx zyvox expir -develop emerg infectionsvfend settlement gener enter market eu lc ex fx vfend expir develop emerg market new form patent exp eu lc ex fx zosyn exp develop emerg antibioticzithromax patent expir eu lc ex fx zithromax develop patent expir emerg spectrum antibiot declinetygacil expir eu lc ex fx tygacil expir develop emerg seriou gram anerob atyp resist infectionsmerrem expir eu lc ex fx merrem expir merrem develop canada australia new zealandmerrem emerg antibiot record incom account hurdl avi beta lactamas inhibitor/cephalosporin seriou infect approv june ciai/cuti right record incom account hurdl antifung esophag lactamas inhib /cephalosporin mrsa phase ii extend spectrum cephalosporin pneumonia/skin infecti launch file foreign patent macrolid antibiot declin sale due moderate/sever essenti cowen
compani data cowen compani
essenti eu lc ex fx lyrica gad patent expir pain patent expir competit pressurestot luanch eu lc ex fx pristiq develop emerg depress market grow modestli vasomotor symptom indic withdrawnzoloft competit pressureszoloft eu lc ex fx zoloft expir februari develop japan possibl zoloft emerg expir eu lc ex fx geodon develop emerg adjunct bipolar depressioneffexor gener competit post eu lc ex fx effexor expir major marketseffexor develop file withdrawneffexor emerg depress market grow modestlyaricept eu lc ex fx aricept sale licens agreementaricept develop emerg gener competit xr form xr patent anxieti drug off-pat sold right eletriptan patent expir newer anti-epilepsi intern growth help off-set essenti cowen
compani data cowen compani
essenti patent expir multipl gener launchedcelebrex eu lc ex fx celebrex expir develop emerg coxibcoxib essenti franchiseflector nsaid topic patch acut inflammatori hemostat post-surg wound gener competit pain essenti gener launch june eu lc ex fx aromasin develop emerg breast cancer breast cancer adjuv therapi colorect tumor devel pat exp europ cancer solid tumor gener competit foreigntot essenti cowen
compani data cowen compani
essenti expir eu lc ex fx xalatan develop emerg glaucoma xalcom edema degener ex right ositot essenti eu lc ex fx premarin develop emerg world-wide dose supportsmedrol eu lc ex fx medrol develop emerg estrogen launch eu japan ibd market rheumatoid arthriti en tab agent type ii diabet combo-therapydepo expir tough formulationglucotrol formul offset gener eros xl patent exp franchis declin partli off-set intern growthoth essenti cowen
compani data cowen compani
essenti drugsviagra launch ciali gener includ canada move eh eu lc ex fx viagra expir develop emerg treatment meddetrol la/detrol launch la/detrol eu lc ex fx detrol la/detrol la/detrol develop la/detrol emerg la/detrol bladderrevatio expir revatio eu lc ex fx revatio launch develop emerg essenti cowen
compani data cowen compani
essenti inject inject eu lc ex fx specialti inject inject develop inject emerg em repres signific growth opportunitiesspecialti inject si signific biosimilar presenc growth expectedinfus system system eu lc ex fx infus system system develop system emerg system cash icu share close biosimilar remicad epogen approv herceptin piii avastin humira rituxan biosimilar eu lc ex fx biosimilar biosimilar epogen neupogen remicad approv herceptin posit chmp develop emerg eu lc ex fx develop emerg multi-specialti specialti api essenti essenti total sale total cowen
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio market cap/fre cash flow metric
failur pipelin product intellectu properti challeng econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
risk includ success pipelin product patent expir greater
expect impact ep success streamlin and/or separ busi
structur outcom potenti
